Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMART-ASD: Semaglutide in Youth With Autism Spectrum Disorder and Obesity
NCT07770152Phase 4Not yet recruiting
- Sponsor
- Cincinnati Children's Hospital Medical Center
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 4, open-label trial of semaglutide in obesity (2 arms), sponsored by Cincinnati Children's Hospital Medical Center. Primary endpoints: Percent Change in Body Mass Index at 12 months and Change in Skeletal Muscle Mass at 12 months. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07770152.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07770152.